Fulltext

Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study

Scherrer, Alexandra U. ; von Wyl, Viktor ; Joos, Beda ; Klimkait, Thomas ; Bürgisser, Philippe ; Yerly, Sabine ; Böni, Jürg ; Ledergerber, Bruno ; Günthard, Huldrych F.

In: Journal of Infectious Diseases, 2011, vol. 203, no. 6, p. 791-797

Aggiungi alla tua lista
    Titre
    • Predictors for the Emergence of the 2 Multi-nucleoside/nucleotide Resistance Mutations 69 Insertion and Q151M and their Impact on Clinical Outcome in the Swiss HIV Cohort Study
    Auteur
    • Scherrer, Alexandra U.. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
    • von Wyl, Viktor. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
    • Joos, Beda. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
    • Klimkait, Thomas. University of Basel, Basel
    • Bürgisser, Philippe. Lausanne University Hospital, Lausanne
    • Yerly, Sabine. Geneva University Hospital, Geneva, Switzerland
    • Böni, Jürg. Institute of Medical Virology, Swiss National Center for Retroviruses, University of Zurich, Zurich
    • Ledergerber, Bruno. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
    • Günthard, Huldrych F.. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
    Type de document
    • Postprint
    Langue
    • Inglese
    Publié dans
    • Journal of Infectious Diseases, 2011, vol. 203, no. 6, p. 791-797. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:298562
    Summary
    The 69 insertion and Q151M mutations are multi-nucleoside/nucleotide resistance mutations (MNR). The prevalence among 4078 antiretroviral therapy (ART)-experienced individuals was <1.3%. Combined ART fully prevented MNR in subtype B infections. Case-control studies were performed to identify risk factors. Control subjects were patients with ≥3 thymidine-analogue mutations. The 69 insertion study (27 control subjects, 14 case patients) identified didanosine exposure as a risk (odds ratio, 5.0 per year; P = .019), whereas the Q151M study (which included 44 control subjects and 25 case patients) detected no associations. Following detection, individuals with Q151M tended to have lower suppression rates and higher mortality rates, relative to control subjects. Additional studies are needed to verify these findings in non-subtype B infections